NCT03149822: A reported trial by University of Colorado, Denver
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03149822 |
|---|---|
| Title | Phase I/II Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 28, 2017 |
| Completion date | Dec. 14, 2022 |
| Required reporting date | Dec. 14, 2023, midnight |
| Actual reporting date | Aug. 9, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |